Prevalence of anxiety in the COVID-19 pandemic: An updated meta-analysis of community-based studies

Santabárbara, J. (Universidad de Zaragoza) ; Lasheras, I. ; Lipnicki, D.M. ; Bueno-Notivol, J. ; Pérez-Moreno, M. ; López-Antón, R. (Universidad de Zaragoza) ; De la Cámara, C. (Universidad de Zaragoza) ; Lobo, A. (Universidad de Zaragoza) ; Gracia-García, P. (Universidad de Zaragoza)

Resumen: Background: The unprecedented worldwide crisis caused by the rapid spread of COVID-19 and the restrictive public health measures enforced by some countries to slow down its transmission have severely threatened the physical and mental wellbeing of communities globally.
Methods: We conducted a systematic review and meta-analysis to determine the prevalence of anxiety in the general population during the COVID-19 pandemic. Two researchers independently searched for cross-sectional community-based studies published between December 1, 2019 and August 23, 2020, using PubMed, WoS, Embase, and other sources (e.g., grey literature, manual search).
Results: Of 3049 records retrieved, 43 studies were included. These studies yielded an estimated overall prevalence of anxiety of 25%, which varied significantly across the different tools used to measure anxiety. Consistently reported risk factors for the development of anxiety included initial or peak phase of the outbreak, female sex, younger age, marriage, social isolation, unemployment and student status, financial hardship, low educational level, insufficient knowledge of COVID-19, epidemiological or clinical risk of disease and some lifestyle and personality variables.
Conclusions: As the overall global prevalence of anxiety disorders is estimated to be 7.3% normally, our results suggest that rates of anxiety in the general population could be more than 3 times higher during the COVID-19 pandemic. These findings suggest a substantial impact on mental health that should be targeted by individual and population-level strategies.

Idioma: Inglés

DOI: 10.1016/j.pnpbp.2020.110207

Año: 2021

Publicado en: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 109 (2021), 461766 [14 pp]
ISSN: 0278-5846

Factor impacto JCR: 5.201 (2021)

Categ. JCR: CLINICAL NEUROLOGY rank: 55 / 212 = 0.259 (2021) - Q2 - T1
Categ. JCR: PSYCHIATRY rank: 55 / 157 = 0.35 (2021) - Q2 - T2
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 70 / 279 = 0.251 (2021) - Q2 - T1
Categ. JCR: NEUROSCIENCES rank: 85 / 275 = 0.309 (2021) - Q2 - T1

Factor impacto CITESCORE: 9.5 - Neuroscience (Q1) - Pharmacology, Toxicology and Pharmaceutics (Q1)

Factor impacto SCIMAGO: 1.37 - Pharmacology (Q1) - Biological Psychiatry (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA-FEDER/B15-17R
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/G03-128
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI-19-01874
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/01-0255
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/03-0815
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/06-0617
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/94-1562
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/97-1321E
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/98-0103

Tipo y forma: Artículo (PostPrint)

Área (Departamento): Área Psicología Básica (Dpto. Psicología y Sociología)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Ped.Radio.Sal.Pú.)